Peptidoglycan Recognition Protein 1 (PGLYRP1), also known as TAG-7. is a secreted pattern recognition receptor (PRR) that plays a critical role in innate immunity. It belongs to the PGRP family, which specifically binds to peptidoglycan (PGN), a key component of bacterial cell walls. PGLYRP1 is expressed in immune cells (e.g., neutrophils, macrophages) and epithelial tissues, where it contributes to microbial sensing and host defense. Its antibacterial mechanism involves direct bactericidal activity through PGN hydrolysis or synergistic action with other antimicrobial peptides, as well as modulation of inflammatory responses via interactions with Toll-like receptors (TLRs) or nucleotide-binding oligomerization domain (NOD) pathways.
PGLYRP1 antibodies are essential tools for studying its function in infection, inflammation, and cancer. They enable detection of PGLYRP1 expression in tissues or bodily fluids (e.g., serum, saliva) and are used in techniques like ELISA, Western blotting, immunohistochemistry, and flow cytometry. Commercially available antibodies (polyclonal or monoclonal) are typically raised in rabbits or mice against specific epitopes, often validated using knockout models or blocking assays. Research highlights PGLYRP1's dual role: it protects against bacterial sepsis but may exacerbate chronic inflammation (e.g., rheumatoid arthritis) or tumor progression in certain contexts. Dysregulation of PGLYRP1 has been linked to inflammatory bowel disease, psoriasis, and cancer metastasis, making its antibodies valuable for diagnostic and therapeutic exploration.